US FDA Commissioner Scott Gottlieb is suggesting that biosimilar adoption – and development of future products – can be aided by payers setting aside a portion of sales that will go to biosimilars.
Speaking at the at the Sept. 18 Chasing Cancer Summit hosted by the Washington Post, Gottlieb was asked about the...





